Literature DB >> 15475039

A re-examination of the potential impact of preventive therapy on the public health problem of tuberculosis in contemporary sub-Saharan Africa.

D Guwatudde1, S M Debanne, M Diaz, C King, C C Whalen.   

Abstract

BACKGROUND: To estimate the effect size of tuberculosis preventive therapy (PT) on the public health problem of tuberculosis in contemporary sub-Saharan Africa.
METHODS: A compartmental flow model that considers high levels of tuberculosis and human immunodeficiency virus (HIV) infection in contemporary sub-Saharan Africa was used to assess the impact of PT on the prevalence of tuberculosis and tuberculosis-associated mortality.
RESULTS: Model implementation shows that giving PT to 25% of HIV-positive individuals with latent tuberculosis infection (LTBI) leads to a 3.9% reduction in the prevalence of tuberculosis in 10 years and a 5.1% reduction in 20 years. This intervention also prevents a cumulative total of 3.0% of tuberculosis-associated deaths in a decade and 5.5% in two decades. Doubling PT coverage to 50% approximately doubles the effect size, suggesting a linear relationship within the 20-year period. The effect size is slightly sensitive to changes in level of HIV transmission, level of tuberculosis transmission, and level of case detection and treatment cure rates in the population.
CONCLUSIONS: Contrary to suggestions by previous authors that PT can significantly reduce the public health problem of tuberculosis in sub-Saharan Africa, this model-based analysis suggests that the impact of PT on tuberculosis in the population is likely to be small.

Entities:  

Mesh:

Year:  2004        PMID: 15475039      PMCID: PMC2860297          DOI: 10.1016/j.ypmed.2004.04.008

Source DB:  PubMed          Journal:  Prev Med        ISSN: 0091-7435            Impact factor:   4.018


  32 in total

1.  Problems and solutions for the Stop TB partnership.

Authors:  S M Blower; C L Daley
Journal:  Lancet Infect Dis       Date:  2002-06       Impact factor: 25.071

Review 2.  Interventions to reduce tuberculosis mortality and transmission in low- and middle-income countries.

Authors:  Martien W Borgdorff; Katherine Floyd; Jaap F Broekmans
Journal:  Bull World Health Organ       Date:  2002       Impact factor: 9.408

3.  Tuberculosis 2000-2010: control, but not elimination.

Authors:  C Dye
Journal:  Int J Tuberc Lung Dis       Date:  2000-12       Impact factor: 2.373

4.  Pulmonary tuberculosis in HIV-infected patients presenting with normal chest radiograph and negative sputum smear.

Authors:  F Palmieri; E Girardi; A M Pellicelli; A Rianda; E Bordi; E Busi Rizzi; N Petrosillo; G Ippolito
Journal:  Infection       Date:  2002-04       Impact factor: 3.553

5.  Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in HIV-1-infected individuals: a randomised trial.

Authors:  D W Fitzgerald; M Desvarieux; P Severe; P Joseph; W D Johnson; J W Pape
Journal:  Lancet       Date:  2000-10-28       Impact factor: 79.321

Review 6.  Review of human immunodeficiency virus type 1-related opportunistic infections in sub-Saharan Africa.

Authors:  Charles B Holmes; Elena Losina; Rochelle P Walensky; Yazdan Yazdanpanah; Kenneth A Freedberg
Journal:  Clin Infect Dis       Date:  2003-02-17       Impact factor: 9.079

7.  Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project.

Authors:  C Dye; S Scheele; P Dolin; V Pathania; M C Raviglione
Journal:  JAMA       Date:  1999-08-18       Impact factor: 56.272

8.  Highly active antiretroviral therapy and tuberculosis control in Africa: synergies and potential.

Authors:  Anthony D Harries; Nicola J Hargreaves; Rehab Chimzizi; Felix M Salaniponi
Journal:  Bull World Health Organ       Date:  2002       Impact factor: 9.408

9.  The impact of HIV on tuberculosis control--towards concerted action.

Authors:  Peter Godfrey-Faussett; Helen Ayles
Journal:  Lepr Rev       Date:  2002-12       Impact factor: 0.537

10.  Declining HIV-1 incidence and associated prevalence over 10 years in a rural population in south-west Uganda: a cohort study.

Authors:  S M Mbulaiteye; C Mahe; J A G Whitworth; A Ruberantwari; J S Nakiyingi; A Ojwiya; A Kamali
Journal:  Lancet       Date:  2002-07-06       Impact factor: 79.321

View more
  7 in total

1.  Beneficial and perverse effects of isoniazid preventive therapy for latent tuberculosis infection in HIV-tuberculosis coinfected populations.

Authors:  Ted Cohen; Marc Lipsitch; Rochelle P Walensky; Megan Murray
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-21       Impact factor: 11.205

2.  Impact of isoniazid preventive therapy for HIV-infected adults in Rio de Janeiro, Brazil: an epidemiological model.

Authors:  David W Dowdy; Jonathan E Golub; Valeria Saraceni; Lawrence H Moulton; Solange C Cavalcante; Silvia Cohn; Antonio G Pacheco; Richard E Chaisson; Betina Durovni
Journal:  J Acquir Immune Defic Syndr       Date:  2014-08-15       Impact factor: 3.731

3.  Modeling the joint epidemics of TB and HIV in a South African township.

Authors:  Nicolas Bacaër; Rachid Ouifki; Carel Pretorius; Robin Wood; Brian Williams
Journal:  J Math Biol       Date:  2008-04-15       Impact factor: 2.259

4.  Tracking the rate of initiation and retention on isoniazid preventive therapy in a high human immunodeficiency virus and tuberculosis burden setting of Lesotho.

Authors:  Eltony Mugomeri; Dedré Olivier; Wilhelmiena M J van den Heever
Journal:  S Afr J Infect Dis       Date:  2019-11-25

Review 5.  How can mathematical models advance tuberculosis control in high HIV prevalence settings?

Authors:  R M G J Houben; D W Dowdy; A Vassall; T Cohen; M P Nicol; R M Granich; J E Shea; P Eckhoff; C Dye; M E Kimerling; R G White
Journal:  Int J Tuberc Lung Dis       Date:  2014-05       Impact factor: 2.373

6.  Decreased risk of HIV-associated TB during antiretroviral therapy expansion in rural Eswatini from 2009 to 2016: a cohort and population-based analysis.

Authors:  Bernhard Kerschberger; Michael Schomaker; Alex Telnov; Debrah Vambe; Nicholas Kisyeri; Welile Sikhondze; Lorraine Pasipamire; Siphiwe Mavis Ngwenya; Barbara Rusch; Iza Ciglenecki; Andrew Boulle
Journal:  Trop Med Int Health       Date:  2019-08-07       Impact factor: 2.622

7.  Effect of isoniazid preventive therapy on tuberculosis or death in persons with HIV: a retrospective cohort study.

Authors:  Henok Tadesse Ayele; Maaike S M van Mourik; Marc J M Bonten
Journal:  BMC Infect Dis       Date:  2015-08-13       Impact factor: 3.090

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.